A mobile lung screening unit designed to give patients a better chance by detecting cancer early, has seen about 3,000 people ...

(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in ...

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever ...

Imagine you go to the healthcare provider because you have a bad cough, or maybe you fell and hurt your ribs.

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

Biodesix is focused on the large, underserved lung nodule market with five Medicare-covered tests and estimates ~6 million new nodules annually; it’s expanding into targeted primary care referral ...

With lung cancer the leading cause of cancer death both in the UK and globally, the UK's National Health Service (NHS) has launched a trial of AI lung scan analysis and robot-guided biopsies in an ...

Amini: As a radiation oncologist, I do play a larger role than I feel we used to as our patients are living longer and cure rates are improving. We are no longer just seeing the short or subacute ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...